Business news – Page 102
-
Business
AbbVie emerges from Abbott split
US healthcare giant Abbott has renamed the branded drugs part of its business
-
Business
GSK to build £350m factory in UK
GlaxoSmithKline (GSK) has announced £350 million plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria
-
News
GSK to build £350 million factory in UK
Tax breaks in the UK budget have prompted GSK to reaffirm its commitment
-
News
India green lights production of patented cancer drug
For the first time India has invoked a ‘compulsory licence’ clause to cut the cost of a patented anti-cancer drug
-
FeatureRising from the ashes
Neil Sinclair reports on some exciting new ventures emerging from redundant chemical and pharmaceutical plants
-
OpinionThe elements of drug design
Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
-
Business
Business roundup: March 2012
Pharmaceutical Collaboration for neglected tropical diseases A group of 13 pharma companies, three national governments and several global health organisations has come together to target 10 neglected tropical diseases (NTDs) with $785 million (?497 million) in R&D funding. The group aims to ’accelerate progress toward eliminating or controlling [this set ...
-
Opinion
The language of the lab
Derek Lowe wonders what the lab lingua franca might be in the years to come
-
Business
Business roundup: February 2012
Pharmaceutical BMS spends $2.5 billion on antiviral firm Pharma giant Bristol-Myers Squibb (BMS) has struck a deal to buy US biotech Inhibitex for $2.5 billion (?1.6 billion). The move will stock BMS’s pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating ...
-
Opinion
Rewards of repurposing
Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
-
Business
Business roundup: January 2012
Pharmaceutical Mental health drug use up More than one fifth of adults in the US took a mental health drug of some kind in 2010, according to a new report. The authors from Medco Health Solutions, a US pharmacy services company, found that use was higher for women than for ...
-
-
Business
Business roundup: December 2011
Almac to hire 500 over next 12 months UK contract research organisation (CRO) Almac says that it expects to hire about 500 people in the next 12 months, split between its headquarters in Craigavon, Northern Ireland, and its new US site in Souderton, Pennsylvania. Almac, a privately owned company, is ...
-
Opinion
Compounds in the dark
Derek Lowe discusses the compounds you can buy but won't see anywhere in the literature
-
Business
Business roundup: November 2011
Interview: Gilles Cottier Source: © SAFC The SAFC boss wants to see fewer vendors in the market SAFC president Gilles Cottier wants SAFC to hit $1 billion (£644 million) in sales by 2015, an ambitious target given that the company made $650 million in sales in 2010. ...
-
OpinionCommon sense and safety
You have to make space for good sense when thinking about safety, argues Derek Lowe
-
Business
Business roundup: October 2011
Ireland still attractive to pharma industry Pharma and chemical products represent 50 per cent of Irish exports Less than a year has passed since internal economic turmoil in Ireland culminated in an unprecedented €83 billion (£71 billion) bailout, yet interest in pharma manufacturing in the country seems ...
-
Opinion'Pay for delay'
Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal
-
Business
Business roundup: September 2011
Challenges for the drugs to help you quit Source: © Shutterstock Tobacco kills six million people every year The share price of US-based Nabi Biopharmaceuticals has fallen by 70 per cent after it announced that its nicotine addiction treatment, NicVax, failed to reach its endpoint in the ...
-
OpinionThe pitfalls that prevent progress
Derek Lowe highlights the less visible pitfalls on the road to a new drug